Amgen Inc. (NASDAQ:AMGN) [Trend Analysis] luring active investment momentum, shares a gain 0.77% to $156.74. Amgen (AMGN) revealed that Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis or carfilzomib to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
The CHMP positive opinion is based on data from the Phase 3 head-to-head ENDEAVOR study in which patients with multiple myeloma treated with Kyprolis plus dexamethasone achieved superior progression-free survival (PFS) of 18.7 months compared to 9.4 months in those receiving Velcade (bortezomib) plus dexamethasone.
The most common adverse reactions that occurred in greater than 20 percent of patients in the Kyprolis arm were anemia, fatigue, diarrhea, thrombocytopenia, nausea, pyrexia, dyspnea, respiratory tract infection, cough and peripheral edema. The total volume of 1.36 Million shares held in the session was surprisingly higher than its average volume of 3213.77 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 35.20%, and looking further price to next year’s EPS is 9.17%. While take a short look on price to sales ratio, that was 5.33 and price to earnings ratio of 16.59 attracting passive investors.
Shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) [Trend Analysis] runs in leading trade, it surging 4.60% to traded at $27.50. The firm has price volatility of 6.00% for a week and 6.88% for a month. Portola Pharma presents full results of its Phase 3 APEX study at ISTH SSC Meeting; plans to submit the APEX Study data as part of a NDA and MAA for betrixaban in 2H16 (PTLA).
APEX, which enrolled 7,513 patients at more than 450 clinical sites worldwide, assessed the superiority of extended-duration betrixaban for 35 days compared to standard-duration enoxaparin for 10+4 days. Lead author of the study states, “The APEX Study results show consistent evidence that VTE events can be reduced with betrixaban with no statistical difference in major bleeding between the betrixaban and enoxaparin arms.
This is particularly true for the most clinically relevant symptomatic disease where we observed a 30 to 45 percent reduction in events over the duration of the study,” Narrow down four to firm performance, its weekly performance was 5.32% and monthly performance was 11.97%. The stock price of PTLA is moving up from its 20 days moving average with 12.64% and isolated positively from 50 days moving average with 13.59%.
Several matter pinch shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) [Trend Analysis], as shares surging 1.68% to $0.42 with a share volume of 1.36 Million. Orexigen Therapeutics (OREX) announced that Orexigen co-founder & former Chairman, Eckard Weber, M.D., has resigned from the Board. Dr. Weber served as Chairman from 2002 until earlier this year. From Nov 2008 until March 2009, Dr. Weber also served as interim President and CEO.
The stock is going forward its 52-week low with 19.11% and moving down from its 52-week high price with -91.97%. To have technical analysis views, liquidity ratio of a company was calculated 8.60 as evaluated with its debt to equity ratio of 19.48. The float short ratio was 15.57%, as compared to sentiment indicator; Short Ratio was 9.04.